Abstract
The maintenance of normal blood flow depends completely on the inhibition of thrombin by antithrombin, a member of the serpin family. Antithrombin circulates at a high concentration, but only becomes capable of efficient thrombin inhibition on interaction with heparin or related glycosaminoglycans. The anticoagulant properties of therapeutic heparin are mediated by its interaction with antithrombin, although the structural basis for this interaction is unclear. Here we present the crystal structure at a resolution of 2.5 Å of the ternary complex between antithrombin, thrombin and a heparin mimetic (SR123781). The structure reveals a template mechanism with antithrombin and thrombin bound to the same heparin chain. A notably close contact interface, comprised of extensive active site and exosite interactions, explains, in molecular detail, the basis of the antithrombotic properties of therapeutic heparin.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Stubbs, M.T. & Bode, W. A player of many parts: the spotlight falls on thrombin's structure. Thromb. Res. 69, 1–58 (1993).
Stubbs, M.T. & Bode, W. The clot thickens: clues provided by thrombin structure. Trends Biochem. Sci. 20, 23–28 (1995).
Huntington, J.A. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J. Thromb. Haemost. 1, 1535–1549 (2003).
Hirsh, J. Blood tests for the diagnosis of venous and arterial thrombosis. Blood 57, 1–8 (1981).
Kojima, T. Targeted gene disruption of natural anticoagulant proteins in mice. Int. J. Hematol. 76 (suppl. 2), 36–39 (2002).
Mulloy, B. & Linhardt, R.J. Order out of complexity—protein structures that interact with heparin. Curr. Opin. Struct. Biol. 11, 623–628 (2001).
Lindahl, U., Thunberg, L., Backstrom, G. & Riesenfeld, J. The antithrombin-binding sequence of heparin. Biochem. Soc. Trans. 9, 499–451 (1981).
Casu, B. et al. The structure of heparin oligosaccharide fragments with high anti- (factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem. J. 197, 599–609 (1981).
Rosenberg, R.D. Heparin, antithrombin, and abnormal clotting. Annu. Rev. Med. 29, 367–378 (1978).
Olson, S.T. & Chuang, Y.J. Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc. Med. 12, 331–338 (2002).
Olson, S.T. & Bjork, I. Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects. J. Biol. Chem. 266, 6353–6364 (1991).
Olson, S.T. Quantitative characterization of the thrombin-heparin interaction. J. Biol. Chem. 266, 6342–6352 (1999).
Fareed, J., Hoppensteadt, D.A. & Bick, R.L. An update on heparins at the beginning of the new millennium. Semin. Thromb. Hemost. 26 (suppl. 1), 5–21 (2000).
Bray, B., Lane, D.A., Freyssinet, J.M., Pejler, G. & Lindahl, U. Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin. Biochem. J. 262, 225–232 (1989).
Kelton, J.G. Heparin-induced thrombocytopenia: an overview. Blood Rev. 16, 77–80 (2002).
Petitou, M. et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 398, 417–422 (1999).
Dementiev, A., Simonovic, M., Volz, K. & Gettins, P.G. Canonical inhibitor-like interactions explain reactivity of α1-proteinase inhibitor Pittsburgh and antithrombin with proteinases. J. Biol. Chem. 278, 37881–37887 (2003).
Ye, S. et al. The structure of a Michaelis serpin–protease complex. Nat. Struct. Biol. 8, 979–983 (2001).
Baglin, T.P., Carrell, R.W., Church, F.C., Esmon, C.T. & Huntington, J.A. Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc. Natl. Acad. Sci. USA 99, 11079–11084 (2002).
Schechter, I. & Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157–162 (1967).
Jin, L. et al. The anticoagulant activation of antithrombin by heparin. Proc. Natl. Acad. Sci. USA 94, 14683–14688 (1997).
Chuang, Y.J., Swanson, R., Raja, S.M. & Olson, S.T. Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin. J. Biol. Chem. 276, 14961–14971 (2001).
Zhang, E. & Tulinsky, A. The molecular environment of the Na+ binding site of thrombin. Biophys. Chem. 63, 185–200 (1997).
Sheehan, J.P. & Sadler, J.E. Molecular mapping of the heparin-binding exosite of thrombin. Proc. Natl. Acad. Sci. USA 91, 5518–5522 (1994).
Ye, J., Rezaie, A.R. & Esmon, C.T. Glycosaminoglycan contributions to both protein C activation and thrombin inhibition involve a common arginine-rich site in thrombin that includes residues arginine 93, 97, and 101. J. Biol. Chem. 269, 17965–17970 (1994).
He, X., Ye, J., Esmon, C.T. & Rezaie, A.R. Influence of Arginines 93, 97, and 101 of thrombin to its functional specificity. Biochemistry 36, 8969–8976 (1997).
Tsiang, M., Jain, A.K. & Gibbs, C.S. Functional requirements for inhibition of thrombin by antithrombin III in the presence and absence of heparin. J. Biol. Chem. 272, 12024–12029 (1997).
Dang, Q.D., Guinto, E.R. & Di Cera, E. Rational engineering of activity and specificity in a serine protease. Nat. Biotechnol. 15, 146–149 (1997).
Di Cera, E. et al. The Na+ binding site of thrombin. J. Biol. Chem. 270, 22089–22092 (1995).
Tsiang, M. et al. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Biochemistry 35, 16449–16457 (1996).
Le Bonniec, B.F., Guinto, E.R. & Stone, S.R. Identification of thrombin residues that modulate its interactions with antithrombin III and α 1-antitrypsin. Biochemistry 34, 12241–12248 (1995).
Izaguirre, G., Zhang, W., Swanson, R., Bedsted, T. & Olson, S.T. Localization of an antithrombin exosite that promotes rapid inhibition of factors Xa and IXa dependent on heparin activation of the serpin. J. Biol. Chem. 278, 51433–51440 (2003).
Dementiev, A., Petitou, M., Herbert, J.M. & Gettins, P.G.W. Antithrombin–anhydrothrombin–heparin ternary complex structure reveals the basis of inhibitor specificity. Nat. Struct. Mol. Biol. advance online publication, 15 August 2004 (doi:10.1038/nsmb810).
Johnson, D.J. & Huntington, J.A. The influence of hinge region residue Glu381 on antithrombin allostery and metastability. J. Biol. Chem. 279, 4913–4921 (2004).
Leslie, A.W.G. Joint CCP4 and ESF-EACMB Newsletter on Protein Crystallography Vol. 26 (Daresbury Laboratory, Warrington, UK, 1992).
Vagin, A. & Teplyakov, A. An approach to multi-copy search in molecular replacement. Acta Crystallogr. D 56, 1622–1624 (2000).
McRee, D.E. A visual protein crystallographic software system for X11/XView. J. Mol. Graph. 10, 44–46 (1992).
van Aalten, D.M. et al. PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. J. Comput. Aided Mol. Des. 10, 255–262 (1996).
Brunger, A.T. et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D 54, 905–921 (1998).
Esnouf, R.M. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J. Mol. Graph. Model. 15, 132 (1997).
Merritt, E.A. & Murphy, M.E.P. Raster3d version 2.0: a program for photorealistic molecular graphics. Acta Crystallogr. D 50, 869–873 (1994).
Johnson, D.J. & Huntington, J.A. Crystal structure of antithrombin in a heparin-bound intermediate state. Biochemistry 42, 8712–8719 (2003).
Acknowledgements
The authors are grateful to M. Petitou of Sanofi Synthelabo for providing the heparin mimetic SR123781 for crystallization, and to R. Carrell for comments on the manuscript. Funding for J.A.H. was provided by the NIH (R01 HL68629) and the Medical Research Council (UK), and C.T.E. is a Howard Hughes Investigator.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Li, W., Johnson, D., Esmon, C. et al. Structure of the antithrombin–thrombin–heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol 11, 857–862 (2004). https://doi.org/10.1038/nsmb811
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nsmb811
This article is cited by
-
Self-anticoagulant sponge for whole blood auto-transfusion and its mechanism of coagulation factor inactivation
Nature Communications (2023)
-
A curved host and second guest cooperatively inhibit the dynamic motion of corannulene
Nature Communications (2021)
-
Transient blood thinning during extracorporeal blood purification via the inactivation of coagulation factors by hydrogel microspheres
Nature Biomedical Engineering (2021)
-
Heparin stimulates biofilm formation of Escherichia coli strain Nissle 1917
Biotechnology Letters (2021)
-
Identification and characterization of a novel variant in C-terminal region of Antithrombin (Ala427Thr) associated with type II AT deficiency leading to polymer formation
Journal of Thrombosis and Thrombolysis (2020)